Compare Medpace Holdings Inc (MEDP) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Prologis Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Prologis Inc trades at $129.49 (market cap $122.87B). The key difference: Prologis Inc is far larger — about 7.3× Medpace Holdings Inc's market cap, and Prologis Inc pays a 3.31% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Prologis Inc for 102 Days on average.
| MEDP | PLD | |
|---|---|---|
Market Cap | $16.82B | $122.87B |
Volume | 223,093 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $630.19 | $149.96 |
52-Week Low | $393.42 | $111.23 |
Typical Hold Time | 14 Days | 102 Days |
Enterprise Value | $16.44B | $157.61B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
PLD trades at $129.49, up 1.72% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and three consecutive quarterly earnings beats. The stock is supported by robust leasing activity and data center growth, as highlighted in recent CFO commentary (Defense World, 2026-09-21).
The outlook is positive with a consensus price target of $155.15 (59.52% buy ratings), but risks include rising debt-to-asset ratio (37.2% in 2025) and market volatility. Upside is driven by warehouse demand and data center expansion, while macroeconomic headwinds pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
